Gapping down
In reaction to disappointing earnings/guidance:
- SMCI -21% (offering prelim Q4 results and Q1 outlook; co also provided an update on its Nasdaq listing and SEC filings -- expects stock to be suspended and delisted from Nasdaq), GSM -6.3% (also authorized the repurchase of up to $20 million of ordinary shares in the period ending December 31, 2018), RRGB -3.7%, LOW -2.2%, SE -1.3%
Other news:
- HA -3.9% (Category 4 Hurricane Lane might have some impacts on Hawaii)
- MNK -2.3% (receives Complete Response Letter from the FDA related to its New Drug Application for stannsoporfin)
- AGN -1% (receives Complete Response Letter from the FDA for ulipristal acetate New Drug Application, citing safety concerns regarding ESMYA post-marketing reports outside the US)
Analyst comments:
- JILL -3.5% (downgraded to Market Perform at Cowen)
- FNSR -2.4% (downgraded to Mkt Perform from Outperform at Raymond James)
- CTL -1.6% (downgraded to Sell from Neutral at MoffettNathanson)
- ZTS -1.4% (downgraded to Hold from Buy at Stifel)
- SBUX -0.9% (downgraded to Neutral from Overweight at Piper Jaffray)
- T -0.6% (downgraded to Market Perform from Outperform at Wells Fargo)
![]()